Abstract:Vascular endothelial growth factor (VEGF) is one of the most significant mediators of angiogenesis, which interacts with a specific membrane receptor: VEGF receptor 2 (VEGFR2). Studies elsewhere have shown that, a VEGF-blocker can regulate several vital processes of tumor promotion. However, there is no literature evidence of investigation on antiangiogenic ability of single domain 3 of VEGFR-2 (VEGFR2 D3), as the key domain in signal transduction of VEGF. In this article, we aimed at developing an efficient method for producing soluble form of this receptor as therapeutic applications. The optimization of the production of soluble VEGFR2 D3 in Escherichia coli was firstly done by testing the periplasmic expression in different expression systems using three osmotic shock methods. To enhance the yield, vital factors were selected from nine factors by Plackett–Burman design and the level of each viral factor was optimized via a response surface methodology based central composite design. After purification and identification of the protein, the bioactivity assays: quantitative ELISA, VEGF-induced proliferation and in vivo chick chorioallantoic membrane assay were employed in our study. The outcome showed that, E. coli Rosetta-gami (DE3)/pET22b-VEGFR2 D3 was the most effective expression system. Furthermore, the inducing time, peptone and glycerol concentration affected the periplasmic expression of VEGFR2 D3 significantly. The corresponding level was also optimized. The bioactivity assay studies showed VEGFR2 D3 could suppress both VEGF stimulated cell proliferation in vitro and neovascularization in vivo. We have therefore provided a novel antiangiogenic drug candidate relating to VEGF-VEGFR2 pathway.

Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia Coli

Expression of Soluble Vascular Endothelial Growth Factor Receptor-2 and Its Effect on Proliferation of Vascular Endothelial Cells

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Expression and Function Identification of Extracellular Domain 3 of Human Vascular Endothelial Growth Factor Receptor KDR

Prokaryotic Expression of VEGF165 and Preliminary Screening of Anti-VEGF Hybridoma Cell Lines

Construction and Application of Cell-Based Models for Screening Vascular Endothelial Growth Factor Receptor-2 Inhibitors

[Screening for inhibitor of vascular endothelial growth factor from random peptide library].

Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors.

PREPARATION OF RECOMBINANT PROTEIN OF EXTRACELLULAR LIGAND BINDING DOMAINS OF MOUSE VEGF RECEPTOR 2 AND ITS APPLICATION

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

The Screening,Expression and Purification of Single Chain Fv(scFv) Against Vascular Endothelial Growth Factor Receptor 2

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block Vegf-Kdr Binding Using Label-Free Microarray-Based Assays

High-yield expression of human vascular endothelial growth factor VEGF(165) in Escherichia coli and purification for therapeutic applications

Research on Inhibition Activity of a Single Chain Fv (scFv) against Vascular Endothelial Growth Factor Receptor 2

A Combination of 2D Similarity Search, Pharmacophore, and Molecular Docking Techniques for the Identification of Vascular Endothelial Growth Factor Receptor-2 Inhibitors

Expression of human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia pastoris, purification of the expressed product and detection of its biological activity.

Expression,Purification and Identification of a Novel Reconstructed VEGF in Pichia Pastroris

Periplasmic Expression Optimization of VEGFR2 D3 Adopting Response Surface Methodology: Antiangiogenic Activity Study.

Cloning,purification and Activity of Mutant Human Vascular Endothelial Growth Factor(hvegf)